Bli medlem
Bli medlem

Du är här


Neurovive Pharmaceutical: NeuroVive and Arbutus sign termination agreement

Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq
Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company,
today announces that the license agreement with Arbutus Biopharma
(formerly OnCore Biopharma, Inc.) has been terminated and all rights
to the NVP018 compound have been reverted back to NeuroVive. The
agreement, signed in 2014, was related to the development and
commercialization of NeuroVive's compound NVP018 for oral treatment
of Hepatitis B viral infection.

In its portfolio of several Hepatitis B compounds, Arbutus has
previously made the decision to proceed with other compounds and to
discontinue the development of NVP018 for this indication. As a
consequence, the agreement between Arbutus and NeuroVive has now been

Under the termination agreement, NeuroVive will at no cost receive
NVP018 drug product and material produced by Arbutus Biopharma,
representing a value of approximately 1.5 MUSD. Data from preclinical
and CMC development have been transferred. Furthermore, all license
rights to the NVP018 compound have been reverted to NeuroVive for
further development in any potential indication.

"We have appreciated the interactions with Arbutus and there are a
number of valuable learnings that have come out of the preclinical
development activities. As we see several very exciting potential
treatments with NVP018 in areas with unmet medical need, the R&D team
is currently exploring various options for further development of
these opportunities. The material provided by Arbutus will be most
useful in these activities", said Erik Kinnman, CEO of NeuroVive.

About NVP018

NVP018 is a potent non-immunosuppressive cyclophilin inhibitor of the
novel compound class Sangamides. NVP018 is the oral version of
NeuroVive's lead compound from its cyclophilin platform and has
undergone extensive preclinical development and evaluation in various
efficacy models. The drug candidate NVP018 was licensed to a third
party in September 2014, Arbutus Biopharma (formerly OnCore
Biopharma) for oral treatment of Hepatitis B.

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The
company is committed to the discovery and development of medicines
that preserve mitochondrial integrity and function in areas of unmet
medical need. NeuroVive enhances the value of its projects in an
organization that includes strong international partnerships and a
network of mitochondrial research institutions, drug development and
production expertise, as well as commercial partners.

NeuroVive has a project in clinical phase II development for the
prevention of moderate to severe traumatic brain injury (NeuroSTAT®).
NeuroSTAT has orphan drug designation in Europe and in the US. The
R&D portfolio consists of several late stage research programs in
areas ranging from genetic mitochondrial disorders to neurological
and metabolic diseases.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The
share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:

Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or

Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)

This information is information that NeuroVive Pharmaceutical AB
(publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact person set out above, at 08:30 a.m. CEST on
October 21, 2016.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.